ProCE Banner Activity

Precision Therapeutic Strategies in Ovarian Cancer: Updates & Considerations for Managed Care Professionals

Slideset

Download these slides covering the recent clinical developments and FDA approvals, therapeutic strategies for integrating new treatments, and managed care perspectives informing the use of biomarker-directed therapies for patients with ovarian cancer, including PARP inhibitors and antibody–drug conjugates. 

Released: April 26, 2024

Expiration: April 25, 2025

Share

Faculty

Laura R. Bobolts

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida 

Kelly Romo

Kelly Romo, PharmD, BCOP

Manager of Oncology Drug Management
Blue Cross Blue Shield of Michigan
Detroit, Michigan

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and GlaxoSmithKline.

AstraZeneca

GlaxoSmithKline

Partners

Clinical Care Options, LLC

ProCE Banner